Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials

Pooja Ghatalia; Youjin Je; Paul L. Nguyen; Quoc Dien Trinh; Toni K. Choueiri; Guru Sonpavde

doi:10.1016/j.critrevonc.2015.03.006

Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials

Pooja Ghatalia
, Youjin Je
, Paul L. Nguyen
, Quoc Dien Trinh
, Toni K. Choueiri
, Guru Sonpavde

Kyung Hee University
Brigham and Women's Hospital
Harvard University
Dana-Farber Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center
Cancer Center
Dana-Farber/Harvard Cancer Center
University of Alabama at Birmingham
University of Central Florida

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was conducted to systematically determine the relative risk (RR) of fatigue, a common side effect associated with single agent therapy with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORi). The RR of all grade fatigue and high grade fatigue in 7304 patients from 19 trials was 1.35 (95% CI 1.22-1.49, p<. 0.001) and 1.33 (95% CI 0.97-1.82, p=. 0.08), respectively in patients receiving VEGFR TKIs or mTORi. The summary incidence of all grade and high grade fatigue in the drug arm was 38.2% (95% CI 31.8-45.1) and 4.0% (95% CI 2.8-5.7), respectively. The type of drug (VEGFR TKI vs. mTORi), line of therapy, age, type of tumor (RCC vs. others) and median duration of therapy did not affect the risk of all-grade fatigue.

Original language	English
Pages (from-to)	251-263
Number of pages	13
Journal	Critical Reviews in Oncology/Hematology
Volume	95
Issue number	2
DOIs	https://doi.org/10.1016/j.critrevonc.2015.03.006
State	Published - Aug 1 2015

Keywords

Fatigue
Mammalian target of rapamycin inhibitors
Meta-analysis
Tyrosine kinase inhibitors
Vascular endothelial growth factor receptor

Access to Document

10.1016/j.critrevonc.2015.03.006

Fingerprint

Dive into the research topics of 'Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials'. Together they form a unique fingerprint.

Cite this

Ghatalia, P., Je, Y., Nguyen, P. L., Trinh, Q. D., Choueiri, T. K., & Sonpavde, G. (2015). Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 95(2), 251-263. https://doi.org/10.1016/j.critrevonc.2015.03.006

Ghatalia, Pooja ; Je, Youjin ; Nguyen, Paul L. et al. / Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies : A meta-analysis of randomized clinical trials. In: Critical Reviews in Oncology/Hematology. 2015 ; Vol. 95, No. 2. pp. 251-263.

@article{4f5438553c9e47ccba4cb6a05d54ed2d,

title = "Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials",

abstract = "A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was conducted to systematically determine the relative risk (RR) of fatigue, a common side effect associated with single agent therapy with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORi). The RR of all grade fatigue and high grade fatigue in 7304 patients from 19 trials was 1.35 (95\% CI 1.22-1.49, p<. 0.001) and 1.33 (95\% CI 0.97-1.82, p=. 0.08), respectively in patients receiving VEGFR TKIs or mTORi. The summary incidence of all grade and high grade fatigue in the drug arm was 38.2\% (95\% CI 31.8-45.1) and 4.0\% (95\% CI 2.8-5.7), respectively. The type of drug (VEGFR TKI vs. mTORi), line of therapy, age, type of tumor (RCC vs. others) and median duration of therapy did not affect the risk of all-grade fatigue.",

keywords = "Fatigue, Mammalian target of rapamycin inhibitors, Meta-analysis, Tyrosine kinase inhibitors, Vascular endothelial growth factor receptor",

author = "Pooja Ghatalia and Youjin Je and Nguyen, \{Paul L.\} and Trinh, \{Quoc Dien\} and Choueiri, \{Toni K.\} and Guru Sonpavde",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ireland Ltd.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.critrevonc.2015.03.006",

language = "English",

volume = "95",

pages = "251--263",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

Ghatalia, P, Je, Y, Nguyen, PL, Trinh, QD, Choueiri, TK & Sonpavde, G 2015, 'Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials', Critical Reviews in Oncology/Hematology, vol. 95, no. 2, pp. 251-263. https://doi.org/10.1016/j.critrevonc.2015.03.006

Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. / Ghatalia, Pooja; Je, Youjin; Nguyen, Paul L. et al.
In: Critical Reviews in Oncology/Hematology, Vol. 95, No. 2, 01.08.2015, p. 251-263.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies

T2 - A meta-analysis of randomized clinical trials

AU - Ghatalia, Pooja

AU - Je, Youjin

AU - Nguyen, Paul L.

AU - Trinh, Quoc Dien

AU - Choueiri, Toni K.

AU - Sonpavde, Guru

PY - 2015/8/1

Y1 - 2015/8/1

N2 - A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was conducted to systematically determine the relative risk (RR) of fatigue, a common side effect associated with single agent therapy with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORi). The RR of all grade fatigue and high grade fatigue in 7304 patients from 19 trials was 1.35 (95% CI 1.22-1.49, p<. 0.001) and 1.33 (95% CI 0.97-1.82, p=. 0.08), respectively in patients receiving VEGFR TKIs or mTORi. The summary incidence of all grade and high grade fatigue in the drug arm was 38.2% (95% CI 31.8-45.1) and 4.0% (95% CI 2.8-5.7), respectively. The type of drug (VEGFR TKI vs. mTORi), line of therapy, age, type of tumor (RCC vs. others) and median duration of therapy did not affect the risk of all-grade fatigue.

AB - A trial-level meta-analysis of randomized phase II/III controlled trials in renal cell carcinoma (RCC) and other malignancies was conducted to systematically determine the relative risk (RR) of fatigue, a common side effect associated with single agent therapy with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORi). The RR of all grade fatigue and high grade fatigue in 7304 patients from 19 trials was 1.35 (95% CI 1.22-1.49, p<. 0.001) and 1.33 (95% CI 0.97-1.82, p=. 0.08), respectively in patients receiving VEGFR TKIs or mTORi. The summary incidence of all grade and high grade fatigue in the drug arm was 38.2% (95% CI 31.8-45.1) and 4.0% (95% CI 2.8-5.7), respectively. The type of drug (VEGFR TKI vs. mTORi), line of therapy, age, type of tumor (RCC vs. others) and median duration of therapy did not affect the risk of all-grade fatigue.

KW - Fatigue

KW - Mammalian target of rapamycin inhibitors

KW - Meta-analysis

KW - Tyrosine kinase inhibitors

KW - Vascular endothelial growth factor receptor

UR - https://www.scopus.com/pages/publications/84937514381

U2 - 10.1016/j.critrevonc.2015.03.006

DO - 10.1016/j.critrevonc.2015.03.006

M3 - Review article

C2 - 25900071

SN - 1040-8428

VL - 95

SP - 251

EP - 263

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 2

ER -

Ghatalia P, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology. 2015 Aug 1;95(2):251-263. doi: 10.1016/j.critrevonc.2015.03.006

Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this